Drug Trial Radar · NCT07503587
Evaluating the Efficacy and Safety of of HSK44459 in People With Progressive Pulmonary Fibrosis
Last checked: Nov 19, 2026Latest source record: Mar 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
378
Planned (sponsor's estimate)
Start
Apr 5, 2026
Primary completion
Dec 30, 2028
Study completion Mar 1, 2029
Sponsor
- Lead sponsor
- Haisco Pharmaceutical Group Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 31, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is open to adults with PPF . The main objective is to evaluate of the efficacy and the secondary objective is to evaluate the safety and pharmacokinetic.
Conditions
- Progressive Pulmonary Fibrosis
Interventions
HSK44459Drug
HSK44459 taken orally twice daily in the morning and in the evening for 52weeks.
PlaceboDrug
Placebo matching HSK44459 taken orally twice daily in the morning and in the evening for 52 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- The change from baseline in forced vital capacity (FVC) at week 52Time frame: day 1 and week 52
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.